Adherence to protective cardiovascular medications is of huge importance in the prevention of serious morbidity and mortality . This study seeks to identify factors that influence adherence to the treatment of cardiovascular medications and to analyse the characteristics of the baseline non-adherence Irish cohort of the UMPIRE study. UMPIRE (“Use of a Multidrug Pill In Reducing cardiovascular Events”) was a prospective, randomised, open-label, blinded-endpoint (PROBE) clinical trial carried out in three locations in Europe (Ireland, The Netherlands and the UK) as well as India. The Irish cohort was a total of 333 participants (total trial 2,004 of which half in India). It had a key eligibility criterion of established cardiovascular disease (CVD) or an estimated 5-year CVD risk of ≥15%. The results were present at the American Heart Association 2012 Scientific Sessions.